eNEWSLETTER SIGNUP
Sign up for our free
Industry eNewsletters
Q+A CENTER
Latest question:
How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
Medical Imaging
Most Read
Most E-mailed
E-mail Article
Print Article
Toshiba Provides Johns Hopkins Aplio CV Ultrasound System For Use in Groundbreaking Clinical Trial
TUSTIN, Calif., Nov. 7, 2005 - A leader in ultrasound technology innovation, Toshiba America Medical Systems, Inc. (TAMS), today announced an agreement to provide Johns Hopkins Bayview Medical Center the state-of-the-art Aplio CV ultrasound system for use in a groundbreaking clinical trial. The Aplio CV, Toshibas all-digital ultrasound system for advanced cardiac applications, will enable clinicians in the Johns Hopkins Bayview Medical Center, Department of Non-invasive Cardiac Imaging, to conduct a high-volume of cardiovascular echocardiography procedures.
Under the terms of the agreement, the Aplio CV will be used for 30 months in a clinical study in conjunction with Toshibas Aquilion 64 CFX, the worlds only true volumetric 64-slice computerized tomography (CT) system. The clinical trial, entitled "The Combined Use of Tissue Doppler Echo and Cardiac Multi-Detector CT to Assess Outcome Following Resynchronization Therapy," commenced in October and involves approximately 50-100 patients. According to investigators, no other study has evaluated both ultrasound and CT.
The overall objective of the study is to utilize the combination of these modalities to optimize cardiac resynchronization, predict the adequacy of response to therapy and to study the effects of dyssynchrony.
The study aims to determine which echocardiography measurement or combination of measurements best predicts CT-determined reverse-remodeling in cardiac patients undergoing resynchronization therapy and exploring whether coronary venous anatomy predicts CT determined reverse-remodeling in cardiac patients undergoing resynchronization therapy.
The combination of cardiac CT and Tissue-Doppler echocardiography has the potential to obtain almost all clinically important cardiac information needed to evaluate the patient, plan the implantation procedure and assess the outcome, said Gordon Parhar, director, Ultrasound Business Unit, TAMS. The decision by Johns Hopkins, the No. 1 rated hospital in the country, to utilize not one, but two of our systems for this unique study, validates Toshibas superior technology and excellent clinical support team.
